Prognostic factors and radiographic outcomes of nontuberculous mycobacterial lung disease in rheumatoid arthritis

Journal of Rheumatology

Volumn 40, Issue 8, 2013, Pages 1307-1315

  Yamakawa, Hideaki ^a   Takayanagi, Noboru ^a   Miyahara, Yosuke ^a   Ishiguro, Takashi ^a   Kanauchi, Tetsu ^b   Hoshi, Toshiko ^b   Yanagisawa, Tsutomu ^a   Sugita, Yutaka ^a  

^a Saitama Cardiovascular and Respiratory Center ^*  (Japan)

^b Saitama Cardiovascular and Respiratory Center   (Japan)

Author keywords

Drug toxicity; Nontuberculous mycobacterial lung disease; Prognostic factors; Radiologic deterioration; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM GORDONAE; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; NONHUMAN; NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR;

DRUG TOXICITY; NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE; PROGNOSTIC FACTORS; RADIOLOGIC DETERIORATION; RHEUMATOID ARTHRITIS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84881427804     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121347     Document Type: Article

References (30)

1. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc 2007;4:443-8.
2. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
3. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and pulmonary fibrosis. Rheumatology 2007;46:350-7.
4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum 2002;46:2287-93.
5. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, et al. Association of methotrexate and tumor necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010;69:380-6.
6. Winthrop KL, Yamashita S, Beekman SE, Polgreen PM. Mycobacterial and other serious infections in patients receiving anti-TNF and other newly approved biologic therapies: Case-finding via the Emerging Infectious Network. Clin Infect Dis 2008;46:1738-40.
7. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013;72:37-42.
8. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010; 6:644-52.
9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
10. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
11. Takayanagi N, Tsuchiya Y, Tokunaga D, Miyahara Y, Yamaguchi S, Saito H, et al. Pulmonary infections in patients with rheumatoid arthritis [Japanese]. Nihon Kokyuki Gakkai Zasshi 2007;45:465-73.
12. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
13. Yamakawa H, Takayanagi N, Miyahara Y, Kato E, Kurita Y, Ota C, et al. Clinical course and long-term prognosis of pulmonary nontuberculous mycobacterium with rheumatoid arthritis [abstract]. Ann Japanese Resp Soc 2012;1:S292.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
15. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;185:575-83.
16. Andréjak C, Thomsen VØ, Johansen IS, Riis A, Benfield TL, Duhaut P, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: Incidence and prognostic factors. Am J Respir Crit Care Med 2010;181:514-21.
17. Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense, and M. xenopi in HIV negative patients: Rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001;56:167-72.
18. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
19. van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994;53:224-8.
20. Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res 2011; 63:373-82.
21. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: A report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 2011;38:1258-64.
22. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616-23.
23. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331-9.
24. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Interim analysis of 3881 patients. Ann Rheum Dis 2011;70:2148-51.
25. Maimon N, Brunton J, Chan AK, Marras TK. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 2007;62:739-40.
26. Mufti AH, Toye BW, Mckendry RR, Angel JB. Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis 2005;53:233-8.
27. Kitada S, Uenami T, Yoshimura K, Tateishi Y, Miki K, Miki M, et al. Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Int J Tuberc Lung Dis 2012:16:660-4.
28. Mori S, Tokuda H, Sakai F, Johkoh T, Mimori A, Nishimoto N, et al. Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: A retrospective multicenter study in Japan. Mod Rheumatol 2012;22:727-37.
29. Koike R, Takeuchi T, Eguchi K, Miyasaka N; Japan College of Rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007;17:451-8.
30. Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2012;25:218-27.